UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2024
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
01
November 2024 - “Director/PDMR
Shareholding”
|
99.1
Haleon plc: Director/PDMR
Shareholding
1 November 2024: Haleon
plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces
notification and public disclosure in accordance with the
requirements of The UK Market Abuse Regulation of Transactions by a
Person Discharging Managerial Responsibilities
("PDMR").
This notification sets out the details of the grants of Haleon
share awards over ordinary shares (grant date - 31 October 2024)
made to Dawn Allen as CFO (incoming), under the Haleon Performance
Share Plan 2023 and Share Value Plan 2023.
Further to the announcement on 24 April 2024, relating to Dawn's
appointment as CFO with effect from 1 November 2024, Dawn has
received awards to compensate the loss of incentive payments from
her previous employment. These awards will vest subject to
continued employment and performance conditions where appropriate,
and will mirror as closely as possible the value, terms and release
timeline of the forfeited awards.
In addition, a Performance Share Plan (Interim) award has been
granted on a pro-rated basis to reflect Dawn's start date of 28
October 2024. This award is subject to continued employment
and performance conditions over the performance period ending 31
December 2026 (vesting in March 2027). Performance targets were
disclosed in the 2023 Annual Report and Form 20-F.
All awards are subject to malus and clawback
provisions.
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
|||||
|
a)
|
Name
|
Dawn Allen
|
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Chief Financial Officer (incoming)
|
||||
|
b)
|
Initial notification /Amendment
|
Initial Notification
|
||||
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction
monitor
|
|||||
|
a)
|
Name
|
Haleon plc
|
||||
|
b)
|
LEI
|
549300PSB3WWEODCUP19
|
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|||||
|
a)
|
Description of the financial instrument, type of
instrument
|
Ordinary Shares of £0.01 each
|
||||
|
|
|
|||||
|
Identification code
|
GB00BMX86B70
|
|||||
|
|
|
|||||
|
b)
|
Nature of the transaction
|
(i)
Grant of a
conditional award under the Haleon plc Performance Share Plan
(Buyout) subject
to performance conditions over a performance period ending 31 March
2025 (vesting in June 2025, with
an additional post vest 2 year holding period).
(ii)
Grant of a
conditional award under the Haleon plc Performance Share Plan
(Buyout) subject
to performance conditions over the performance period ending on 31
December 2025 (vesting in June 2026 with
an additional post vest 2 year holding period).
(iii)
Grant of a conditional award
under the Haleon plc Performance Share Plan
(Buyout) subject
to performance conditions over the performance period ending on 31
December 2026 (vesting in June
2027 with an additional post vest 2 year holding
period).
(iv)
Grant of a
conditional award under the Haleon plc Share Value Plan (Buyout)
vesting in November 2024 (with
an additional post vest 2 year holding period).
(v)
Grant of a conditional award
under the Haleon plc Share Value Plan (Buyout) vesting
in June 2025.
(vi)
Grant of a
conditional award under the Haleon plc Performance Share Plan
(Interim) subject
to performance conditions over the performance period ending on 31
December 2026 (vesting in March 2027 with an additional post vest 2
year holding period).
|
||||
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
|
(i)
|
Nil
|
355,191
|
|
|
|
|
|
(ii)
|
Nil
|
334,272
|
|
|
|
|
|
(iii)
|
Nil
|
190,369
|
|
|
|
|
|
(iv)
|
Nil
|
158,653
|
|
|
|
|
|
(v)
|
Nil
|
41,484
|
|
|
|
|
|
(vi)
|
Nil
|
170,334
|
|
|
|
|
|
|
|
|
||
|
d)
|
Aggregated information
|
|
||||
|
|
|
|||||
|
- Aggregated volume
|
1,250,303
|
|||||
|
|
|
|||||
|
- Price
|
Nil
|
|||||
|
|
|
|||||
|
e)
|
Date of the transaction
|
31 October 2024
|
||||
|
f)
|
Place of the transaction
|
Outside a trading venue
|
||||
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans five major categories - Oral Health, Pain
Relief, Respiratory Health, Digestive Health and Other, and
Vitamins, Minerals and Supplements (VMS). Its long-standing brands
- such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin,
Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date: November 01,
2024
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|